Zenas BioPharma (NASDAQ:ZBIO) Stock Keeps “Buy” Rating at HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $44.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 64.01% from the company’s current price.

A number of other research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Zenas BioPharma in a report on Tuesday, October 6th. Wedbush restated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a report on Wednesday, September 30th. Guggenheim reiterated a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a research note on Wednesday, September 30th. Citigroup lifted their price target on shares of Zenas BioPharma from $41.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, September 30th. Finally, Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Zenas BioPharma Stock Up 1.6%

Shares of ZBIO stock traded up $0.43 during trading on Tuesday, reaching $26.83. The company’s stock had a trading volume of 35,727 shares, compared to its average volume of 811,789. The company has a debt-to-equity ratio of 1.57, a current ratio of 9.93 and a quick ratio of 9.93. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -2.97 and a beta of -0.90. The stock’s 50-day moving average price is $30.71 and its 200 day moving average price is $25.37. Zenas BioPharma has a 1-year low of $13.50 and a 1-year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The company had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $15.00 million. On average, research analysts anticipate that Zenas BioPharma will post -5.81 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in Zenas BioPharma in the second quarter worth approximately $49,000. Jupiter Topco LLC purchased a new position in Zenas BioPharma in the second quarter worth approximately $201,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Zenas BioPharma during the 2nd quarter worth approximately $204,000. Bank of New York Mellon Corp lifted its position in shares of Zenas BioPharma by 17.5% during the 1st quarter. Bank of New York Mellon Corp now owns 60,864 shares of the company’s stock worth $1,190,000 after buying an additional 9,062 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Zenas BioPharma during the 1st quarter worth approximately $242,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.